Markey study: Betamethasone could improve outcomes for prostate cancer radiation therapy
A new study published by University of Kentucky Markey Cancer Center researchers suggests that the common steroid betamethasone could be used to reduce unwanted side effects of radiation treatments for prostate cancer.
The research was published in the International Journal of Molecular Sciences June 8.
The lab study led by Luksana Chaiswing, Ph.D., assistant professor in the UK College of Medicine’s Department of Toxicology and Cancer Biology, is the first to demonstrate that betamethasone protects normal prostate cells from injury induced by radiation therapy, while making the cancer cells more susceptible to the treatment.
Prostate cancer is the second leading cause of cancer deaths among men in the U.S. While radiation therapy is important to control the growth of prostate cancer, it presents a significant risk of increasing unwanted side effects, including injury to normal tissues.
“New therapies aimed at protecting against normal tissue injury while also increasing radiation therapy effectiveness are urgently needed,” Chaiswing said. “The development of such approaches would have a major impact on prostate cancer control and the quality of life of patients.”
The team screened around 700 Food and Drug Administration-approved drugs for properties including protecting non-cancer cells against radiation therapy induced cytotoxicity, killing prostate cancer cells and increasing hydrogen peroxide levels in both cancer and non-cancer cells.
Betamethasone, a corticosteroid that is approved for treatment of inflammation and cancer of the hematopoietic system, was one of the top five drugs with all of the desired properties.
Betamethasone increases hydrogen peroxide levels, which activates a protective protein called “RelB” in normal, non-cancerous prostate cells.
“The outcome of this project could lead to a new anticancer regimen that improves the efficacy of radiation therapy by sensitizing tumor tissue to radiation while simultaneously protecting normal tissue from radiation-induced side effects, which could lead to improved quality of life for cancer survivors,” Chaiswing said.
Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers R01CA205400 and R01CA251663, the National Institute of General Medical Sciences of the National Institutes of Health under Award Number P20GM121327, and the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Numbers UL1TR000117 and UL1TR001998. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
